# Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study

> **NCT05028231** · — · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Therapies

## Interventions

- **PROCEDURE:** Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy

## Key facts

- **NCT ID:** NCT05028231
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028231, "Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05028231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*